Targeting HER2 / HER3 co‐mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy
Cancer Reports · 2024
DOI: 10.1002/cnr2.1954 ↗Kurz gefasst
Fallbericht in der Zeitschrift Cancer Reports, 2024. Verfasst von Page E Blas und 8 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Oncology Research Coordination, Baylor Scott and White Research Institute, Dallas, Texas, USA. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Overexpression of HER2 plays an important role in cancer progression and is the target of multiple therapies in HER2‐positive breast cancer. Recent studies have also highlighted the presence of activating mutations in HER2 , and HER3 that are predicted to enhance HER2 downstream pathway activation in a HER2‐dependent manner.
Methods
In this report, we present two exceptional responses in hormone receptor‐positive, HER2 ‐nonamplified, HER2/HER3 co‐mutated metastatic breast cancer patients who were treated with the anti‐HER2‐directed monoclonal antibodies, trastuzumab and pertuzumab.
Results
Both patients acheived exceptional responses to treatment, suggesting that combined trastuzumab, pertuzumab, and endocrine therapy could be a highly effective therapy for these patients and our observations could help prioritize trastuzumab deruxtecan as an early therapeutic choice for patients whose cancers have activating mutations in HER2.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Oncology Research Coordination, Baylor Scott and White Research Institute, Dallas, Texas, USA.
- Department of Translational Science, Tempus Labs Inc., Chicago, Illinois, USA.
- Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia, USA.
- Breast Cancer Research Program, Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, Texas, USA.
ORCID-Profile: Page E Blas
Zitieren
APA
Blas, P. E., Rodriguez, E. S. R., Williams, H. L., Levin, M. K., Bell, J. S. K., Pierobon, M., Barrett, A. S., Petricoin, E. F., & O'Shaughnessy, J. A. (2024). Targeting HER2 / HER3 co‐mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy. Cancer Reports. https://doi.org/10.1002/cnr2.1954
Vancouver
Blas PE, Rodriguez ESR, Williams HL, Levin MK, Bell JSK, Pierobon M, et al. Targeting HER2 / HER3 co‐mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy. Cancer Reports. 2024. doi:10.1002/cnr2.1954
BibTeX
@article{Blas2024,
author = {Blas, Page E and Rodriguez, Esther San Roman and Williams, Heather L and Levin, Maren K and Bell, Joshua S K and Pierobon, Mariaelena and Barrett, Alexander S and Petricoin, Emanuel F and O'Shaughnessy, Joyce A},
title = {Targeting HER2 / HER3 co‐mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy},
journal = {Cancer Reports},
year = {2024},
doi = {10.1002/cnr2.1954}
}
EUVIMED